Gadoteridol
Description
Name: Gadoteridol
Type: small molecule
Groups: approved
Indication: Gadoteridol is an MRI contrast agent used for contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.
Accession Number: DB00597 ( APRD00992)
Description: Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
Structure:
Prescription Products:
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
International Brands
Brand Names
Brand Mixtures
Categories
Type: small molecule
Groups: approved
Indication: Gadoteridol is an MRI contrast agent used for contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.
Accession Number: DB00597 ( APRD00992)
Description: Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
Structure:
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Prohance | injection, solution | 279.3 mg/mL | intravenous | 16-11-1992 | US | |
| Prohance - Liq IV 279.3mg/ml | solution | 279.3 mg | intravenous | 08-09-1998 | Canada | |
| Prohance Liq IV 279.3mg/ml | liquid | 279.3 mg | intravenous | 31-12-1993 | 30-07-1998 | Canada |
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Prohance | injection, solution | 279.3 mg/mL | intravenous | 16-11-1992 | US | |
| Prohance - Liq IV 279.3mg/ml | solution | 279.3 mg | intravenous | 08-09-1998 | Canada | |
| Prohance Liq IV 279.3mg/ml | liquid | 279.3 mg | intravenous | 31-12-1993 | 30-07-1998 | Canada |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|---|
| Prohance | Gadoteridol |
| Prohance - Liq IV 279.3mg/ml | Gadoteridol |
| Prohance Liq IV 279.3mg/ml | Gadoteridol |
| Brand Name | Ingredients |
|---|---|
| Prohance | Gadoteridol |
| Prohance - Liq IV 279.3mg/ml | Gadoteridol |
| Prohance Liq IV 279.3mg/ml | Gadoteridol |
Categories
- Contrast Media
Pharmacology
Indication: Gadoteridol is an MRI contrast agent used for contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.
Pharmacodynamics: Not Available
Mechanism of action: Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record two different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time). In MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Gadoteridol does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
Absorption: Not Available
Volume of distribution:
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Gadoteridol is eliminated in the urine with 94.4 ± 4.8% (mean ± SD) of the dose excreted within 24 hours post-injection.
Half life: Distribution 12 minutes (mean), elimination 100 minutes (mean).
Clearance: Not Available
Toxicity: Not Available
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record two different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time). In MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Gadoteridol does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
Absorption: Not Available
Volume of distribution:
- 204 ± 58 mL/kg
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Gadoteridol is eliminated in the urine with 94.4 ± 4.8% (mean ± SD) of the dose excreted within 24 hours post-injection.
Half life: Distribution 12 minutes (mean), elimination 100 minutes (mean).
Clearance: Not Available
Toxicity: Not Available
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Bracco diagnostics inc
Packagers:
Dosage forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | intravenous | 279.3 mg/mL |
| Solution | intravenous | 279.3 mg |
| Liquid | intravenous | 279.3 mg |
| Form | Route | Strength |
|---|---|---|
| Injection, solution | intravenous | 279.3 mg/mL |
| Solution | intravenous | 279.3 mg |
| Liquid | intravenous | 279.3 mg |
Prices
| Unit description | Cost | Unit |
|---|---|---|
| Prohance 279.3 mg/ml vial | $6.81 | ml |
| Unit description | Cost | Unit |
|---|---|---|
| Prohance 279.3 mg/ml vial | $6.81 | ml |
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|---|---|---|
| 1341176 | Canada | 2001-01-30 | 2018-01-30 |
| 5474756 | United States | 1992-12-12 | 2012-12-12 |
| 5846519 | United States | 1995-12-08 | 2015-12-08 |
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|
| Drug | Interaction |
|---|
Food Interactions:
- Not Available
Taxonomy
Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- 1,2-aminoalcohols
- Azacyclic compounds
- Carbonyl compounds
- Carboxylic acid salts
- Carboxylic acids
- Hydrocarbon derivatives
- Organic salts
- Organic zwitterions
- Secondary alcohols
- Trialkylamines
- Tricarboxylic acids and derivatives
substituent:
- 1,2-aminoalcohol
- Alcohol
- Aliphatic heteromonocyclic compound
- Alpha-amino acid
- Amine
- Azacycle
- Carbonyl group
- Carboxylic acid
- Carboxylic acid salt
- Hydrocarbon derivative
- Organic salt
- Organic zwitterion
- Organoheterocyclic compound
- Organonitrogen compound
- Organooxygen compound
- Secondary alcohol
- Tertiary aliphatic amine
- Tertiary amine
- Tricarboxylic acid or derivatives
References
Synthesis Reference: Not Available
General Reference: Not Available
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: Not Available
External Links:
| Resource | Link |
|---|
| Resource | Link |
|---|
ATC Codes:
- Array
AHFS Codes:
- 92:00.00
MSDS: Download